Background: TROP2 (TACSTD2) is a therapeutic target of antibody-drug conjugates and is broadly expressed in epithelial malignancies. Data on TROP2 protein expression in large, clinically annotated prostate cancer cohorts, particularly in recurrent disease, remain limited. Methods: TROP2 immunohistochemistry was performed on a prostate cancer tissue microarray comprising 17,747 primary radical prostatectomy specimens and 258 recurrent prostate cancer samples.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jonathan
Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack